Fresenius Medical Care AG & Co. KGaA (FMS) Stock: Price, Forecast & Analyst Target
Fresenius Medical Care AG & Co. KGaA (FMS) — MoonshotScore 80/100 (Exceptional band), calculated Nov 18, 2026. Price $20.13 (-3.91%), as of the Nov 19, 2026 trading session; market cap $10.5B. Expected results Feb 23, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Fresenius Medical Care AG & Co. KGaA · FMS · NYSE · Healthcare · Medical - Care Facilities
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Fresenius Medical Care AG & Co. KGaA (FMS)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, at a dirt-cheap price, though the balance sheet is only middling; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Solid; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Rising.
- EPS beat 0 of the last 4 reports
- Altman Z 1.71 · Piotroski F 8
- ROE 7.8% · ROA 3.9% · current ratio 0.99
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 82 | Exceptional | |
| 81 | Exceptional | |
| 82 | Exceptional | |
| 82 | Exceptional | |
| 80 | Exceptional | |
| 80 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $20.13 | |
| Change on the day | -3.91% | |
| 52-week range | $20.02–$26.42 | |
| Market capitalisation | $10.5B | — |
| Price / earnings (trailing) | 13.28 | |
| Shares traded on the day | 2.10M | |
| Beta (volatility vs the S&P 500) | 0.76 | |
| Dividends per share (last 12 months) | $0.86 | |
| Dividend yield (last 12 months) | 3.99% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Based on our prior communications of a stronger first half and more pressured second half, driven by TDAPA headwinds, and that we're 10 months finished with the year, for operating income development, we are narrowing our outlook for 2026.
Shervin Korangy · Statement from
When you look at 2027 from a TDAPA perspective, since we do have now the rate, we do expect an operating income headwind, and it is still a bit early, but because it depends a bit on volume and pricing, on how the drugs develop, but we do expect an operating income headwind for 2027 between EUR 300 million and EUR 350 million based on the expiry that are TDAPA-related.
Martin Fischer · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Fresenius Medical Care AG & Co. KGaA (FMS): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Fresenius Medical Care AG & Co. KGaA (FMS), and what does it report?
Short answer
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Fresenius Medical Care AG & Co. KGaA (FMS) is listed on NYSE. Healthcare / Medical Care Facilities SEC filing business address: Else-Kroener Strasse 1, BAD Homburg, 2M, 61352. It employs 108,165 people and is led by Shervin J. Korangy. The market values it at $10.5B.
What do the latest results show for Fresenius Medical Care AG & Co. KGaA (FMS)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $5.53B Nov 3, 2026
- Latest report · revenue estimate
- $5.52B Nov 3, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 3, 2026
- Latest report · EPS vs estimate
- Below estimate Nov 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 3, 2026 | $5.53B | $5.52B | $0.6400 | $0.6510 |
| Aug 3, 2026 | $5.60B | $5.48B | $0.6600 | $0.6160 |
| May 5, 2026 | $5.40B | $5.41B | $0.5300 | $0.5900 |
| Feb 24, 2026 | $5.97B | $5.67B | $0.8300 | $0.6470 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | €4.88B | €275M | €0.47 (diluted) |
| Q4 FY2025 | €5.07B | €327M | €0.57 (diluted) |
| Q1 FY2026 | €4.61B | €118M | €0.21 (diluted) |
| Q2 FY2026 | €4.86B | €218M | €0.41 (diluted) |
What are the financial strengths and risks for Fresenius Medical Care AG & Co. KGaA (FMS)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 1.71 · Piotroski F 8. Trailing ratios: ROE 7.8% · ROA 3.9% · current ratio 0.99.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.71 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Fresenius Medical Care AG & Co. KGaA (FMS)?
Short answer · as of
The next earnings report is expected on Feb 23, 2027. Current published price targets run low $19.90 · high $25.80 · consensus $23.67 · median $24.50 against a quoted price of $20.13 (as of Nov 19, 2026).
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We will give a qualification when we give the 2027 guidance and outlook.
Martin Fischer ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Fresenius Medical Care AG & Co. KGaA compare with its peers?
Short answer
Fresenius Medical Care AG & Co. KGaA's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $271.34 Nov 18, 2026 | $21.6B | 94 5-pillar Nov 18, 2026 | |
| $13.77 Nov 18, 2026 | $5.24B | 92 5-pillar Nov 18, 2026 | |
| $186.07 Nov 18, 2026 | $10.7B | 91 5-pillar Nov 18, 2026 | |
| $551.33 Nov 19, 2026 | $7.15B | 85 5-pillar Nov 18, 2026 | |
| $31.61 Nov 19, 2026 | $4.74B | 85 5-pillar Nov 18, 2026 | |
| $132.25 Nov 19, 2026 | $13.0B | 81 5-pillar Nov 18, 2026 | |
| Fresenius Medical Care AG & Co. KGaA (FMS) — this page | $20.13 | $10.5B | 80 |
| $156.24 Nov 19, 2026 | $9.83B | 76 5-pillar Nov 18, 2026 | |
| $201.60 Nov 18, 2026 | $3.16B | 76 5-pillar Nov 18, 2026 | |
| $176.59 Nov 19, 2026 | $10.3B | 74 5-pillar Nov 18, 2026 | |
| $68.67 Nov 18, 2026 | $39.5B | 73 5-pillar Nov 18, 2026 | |
| $85.80 Nov 19, 2026 | $14.6B | 66 5-pillar Nov 18, 2026 | |
| $16.26 Nov 19, 2026 | $4.57B | 38 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $19.90 – $25.80
- Consensus target
- $23.67
- Median target
- $24.50
Consensus record · Captured .
Measured against a quoted price of $20.13 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 7.7% Period end Sep 30, 2026
- Previous quarter · ownership
- 7.7% Prior to period end Sep 30, 2026
- Reporting holders
- 231 Period end Sep 30, 2026
- Previous quarter · holders
- 243 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Pzena Investment Management LLC | 16,617,575 |
| Morgan Stanley | 4,424,999 |
| Dodge & Cox | 3,328,110 |
| Brandes Investment Partners, LP | 1,969,749 |
| Todd Asset Management LLC | 1,761,483 |
Tracked investors
Which of the 16 named investors we follow held FMS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported FMS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Fresenius Medical Care AG & Co. KGaA (FMS)?
FMS Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What does Care Enablement contribute to Fresenius Medical Care?
Care Enablement supplies dialysis machines, dialyzers, solutions, bloodlines, medicines and related systems to treatment providers. Management is using Reignite to pursue margin improvement in this business while absorbing inflationary pressure linked to the Middle East conflict.
How does home dialysis fit into Fresenius Medical Care’s model?
Home dialysis extends the company beyond clinic-based treatment: Fresenius Medical Care provides equipment, patient training, clinical oversight, ongoing assistance and coordinated supply deliveries. Demand therefore includes continued support and consumables as well as the initial equipment placement.
What is the FMS stock price today?
The last price recorded for Fresenius Medical Care AG & Co. KGaA (FMS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the FMS price target?
The analyst consensus price target for Fresenius Medical Care AG & Co. KGaA (FMS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does FMS pay a dividend?
Yes. The dividend yield of Fresenius Medical Care AG & Co. KGaA (FMS) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 53 figures on this page — 2 from SEC filings and earnings calls, 42 from Financial Modeling Prep (FMP), 3 with no recorded source, 4 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com